Do you want to read an article? Please log in or register.
HYPOCALCEMIA DURING LENVATINIB TREATMENT FOR ADVANCED THYROID CANCER: CLINICAL FEATURES AND MANAGEMENT IN A REAL-LIFE SETTING
Thyroid
Related content
COMMENTED
Thyroid
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Thyroid
Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK
doi: 10.1089/thy.2020.0944
Thyroid
Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer
Thyroid
Koehler VF, Berg E, Adam P, Weber GL, Pfestroff A, Luster M, Kutsch JM, Lapa C, Sandner B, Rayes N, Fuss CT, Kreissl M, Hoster E, Allelein S, Schott M, Todica A, Fassnacht M, Kroiss M, Spitzweg C
doi: 10.1089/thy.2021.0091
Thyroid
Real world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer
Thyroid.
Koehler V, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, Allelein S, Schott M, Kroiss M, Spitzweg C
doi: 10.1089/thy.2020.0206.
COMMENTED
Thyroid
Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Thyroid
Yansong L, Yang H, Ding Y, Cheng Y, Shi F, Tan J, Deng Z, Chen Z, Wang R, Ji Q, Huang R, Li L
doi: 10.1089/thy.2020.0235
COMMENTED
Type 2 Diabetes
Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries
Diabetes Care.
Overbeek JA, van Herk-Sukel MPP, Vissers PAJ, van der Heijden AAWA, Bronsveld HK, Herings RMC, Schmidt MK, Nijpels G
doi: 10.2337/dc18-2146.
Thyroid
A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules
J Clin Endocrinol Metab.
Angell TE, Maurer R, Wang Z, Kim MI, Alexander CA, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Krane JF, Marqusee E, Moore FD, Nehs MA, Larsen PR, Alexander EK
doi: 10.1210/jc.2019-00664.
Thyroid
Physician specialties involved in thyroid cancer diagnosis and treatment: Implications for improving healthcare disparities
J Clin Endocrinol Metab
Radhakrishnan A, Reyes-Gastelum D, Abrahamse P, Gay B, Hawley ST, Wallner LP, Chen DW, Hamilton AS, Ward KC, Haymart MR
doi: 10.1210/clinem/dgab781
COMMENTED
Thyroid
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
Lancet Diabetes Endocrinol.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A
doi: 10.1016/S2213-
Thyroid
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Lancet Diabetes Endocrinol
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH
doi: 10.1016/S2213-8587(21)00120-0